| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9ac19cb573be06d7d5d84df6f5f1406f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ea205c219c18378d8e487e98bce9c2b1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21cbff64022f95c237c0bd3ec8656ca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ade91498f43631fd02e631c5db9f4dd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d62483d0e3b3d2d8da68758e1cf542f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_31840b64c2f6f6676049271b7499f60a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate |
2007-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4368d0bef5966d097fe4790da0e6aac5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0760d416ff06a25479d101fbac361775
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_741dc6d435e65aac1e091d12ab158216
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f77fc0b23140bb904e5a7c98f342cf8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13313677a2784a3aeadc41ac3464443d |
| publicationDate |
2008-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2008019375-A2 |
| titleOfInvention |
Proteomic patterns of cancer prognostic and predictive signatures |
| abstract |
The invention provides method for predicting whether a cancer patient will respond to a therapy. Methods of the invention may involve examining protein from a cell of the cancer patient by determining the binding of a panel of antibodies to the protein. Methods of the invention may be used to generate both expression and activation profiles for cells from a cancer patient. Profiles from a cancer patient may then be compared to known profiles for therapy responders and non-responders to predict the individual response of the patient. For example, methods of the invention may be used to determine whether an ovarian or breast cancer patient will respond to a therapeutic protocol. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2011525105-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10401364-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9285369-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10473640-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9719995-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8163499-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102016581-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11199546-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2009219437-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8609349-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8658388-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015108639-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9575066-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9250243-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9664683-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8945832-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2618146-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3097421-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9274116-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013117697-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009108637-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008127716-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2011514522-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10527622-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008127716-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10436786-B2 |
| priorityDate |
2006-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |